STAAR Surgical Company 10-K Summary
Reporting period: Fiscal year ended December 28, 2012. The request metadata references “2011 Q4,” but the supplied filing is the fiscal 2012 Form 10-K, filed March 12, 2013. Fiscal 2012 comprised 52 weeks.
Business Context
STAAR designs, manufactures and sells foldable implantable lenses and related delivery systems for ophthalmic surgery. Its principal products are Visian implantable Collamer lenses (ICLs) for refractive surgery and intraocular lenses (IOLs) for cataract surgery. The company operates as one ophthalmic surgical products segment and sells in approximately 60 countries.
- International sales represented 81% of fiscal 2012 revenue.
- ICLs represented approximately 55% of revenue; IOLs represented 41%; other surgical products represented 4%.
- Manufacturing and administrative operations were located in the United States, Switzerland and Japan, with a plan to consolidate manufacturing in Monrovia, California by the end of 2013.
Financial Performance and Key Metrics
| Metric | 2012 | 2011 | Change |
|---|---|---|---|
| Net sales | $63.8 million | $62.8 million | +1.6% |
| Gross profit | $44.3 million | $42.4 million | +4.5% |
| Gross margin | 69.4% | 67.5% | +1.9 percentage points |
| Operating income (loss) | $(1.2) million | $2.8 million | Declined to a loss |
| Income (loss) from continuing operations | $(1.8) million | $1.3 million | Declined to a loss |
| Net income (loss) | $(1.8) million | $1.3 million | Declined to a loss |
| Basic and diluted EPS | $(0.05) | $0.04 | Declined |
| Cash flow from operations | $3.2 million | $5.3 million | Declined |
- ICL revenue increased 9.4% to $35.1 million. Unit volume increased 3% and average selling prices increased 6%; sales outside Korea increased 18%, while Korean sales declined 18%.
- IOL revenue declined 5.7% to $26.0 million, primarily because U.S. IOL volume decreased 25%, partly offset by an 11% increase in average selling prices.
- Marketing and selling expense increased 20.1% to $21.3 million following the addition of 17 sales and marketing employees and increased global marketing activity.
- Research and development expense increased 9.8% to $6.4 million, or 10.1% of revenue.
- Other general and administrative expenses increased to $2.6 million from $1.1 million, primarily reflecting manufacturing-consolidation costs.
- The 2012 tax provision was $1.2 million despite the pretax loss, principally because taxable profits were generated in foreign jurisdictions and U.S. tax-loss benefits remained subject to a full valuation allowance.
Liquidity, Debt and Cash Flow
- Cash and cash equivalents were $21.7 million at year-end, compared with $16.6 million in 2011.
- Working capital increased to $26.2 million from $24.7 million. Current assets were $44.1 million and current liabilities were $17.9 million.
- Operating cash flow was $3.2 million; investing cash flow was $(2.1) million, primarily for property and equipment; financing cash flow was $4.3 million.
- STAAR Japan had $5.9 million outstanding under an unsecured Mizuho line of credit, with no remaining availability at year-end. The facility expires March 28, 2013 and management expected renewal, but provided no assurance.
- A Swiss subsidiary had an undrawn $1.1 million credit facility.
- Total contractual obligations were $18.6 million, including $5.9 million of line-of-credit obligations, $8.4 million of operating leases, $1.4 million of capital leases and $1.5 million of pension obligations.
- Pension plans were underfunded by approximately $3.0 million. The company contributed $234,000 to the Swiss plan in 2012 and paid $65,000 of Japanese plan benefits.
Material Changes Versus 2011
- Revenue growth slowed materially, rising only 1.6% versus 14.2% growth in 2011.
- Product mix continued shifting toward higher-margin ICLs, improving gross margin to 69.4%, but increased marketing, research and consolidation spending caused an operating loss.
- The company moved from 2011 GAAP profitability to a 2012 GAAP loss. It achieved profitability in only the first quarter of 2012.
- Cash increased by $5.1 million, supported by $3.5 million of additional borrowings and $1.5 million from stock-option exercises, despite lower operating cash generation.
- Inventory increased to $11.7 million from $10.9 million, with days of inventory on hand rising to 142 from 129 due partly to safety stock for the manufacturing transition.
- WooJeon Medical, the Korean distributor, remained a significant customer but revenue declined to $6.7 million, or 10.5% of consolidated revenue, from $8.1 million, or 13.0%, in 2011.
- STAAR exited the surgical-pack business and transitioned Spain from distributor sales to a direct-sales model, creating approximately $1.2 million of transition expenses and temporary revenue disruption.
Guidance, Outlook, Risks and Unusual Items
- Management expected to spend approximately 9%–10% of sales on research and development in 2013 and $2.0–$2.5 million on manufacturing consolidation.
- The manufacturing consolidation project was expected to cost approximately $6.0 million in total, with $3.7 million incurred through year-end 2012 and approximately $2.4 million of related capital expenditures expected.
- Management expected the consolidation and tax strategy to improve manufacturing efficiency, margins and utilization of approximately $122.5 million of U.S. federal net operating loss carryforwards, but benefits were not expected to begin until 2014 and were not assured.
- FDA approval of the U.S. Toric ICL remained pending after submission of additional clinical, engineering and software-validation information in November 2012. The company could not predict whether or when approval would be granted.
- Capacity constraints at a third-party acrylic-lens supplier created backlogs for the KS-SP and KS-X preloaded IOLs. The timing of additional supply and qualification of alternatives was uncertain.
- Key risks include dependence on international markets and distributors, foreign-exchange exposure without hedging, elective-procedure demand, intense competition, regulatory delays, product liability and recalls, patent expirations, single-source materials, and concentration of manufacturing in California after consolidation.
- Several important ICL and Collamer-related patents were scheduled to expire between 2014 and 2017, while certain fundamental injector patents were scheduled to expire between 2013 and 2014.
- The company reported an accumulated deficit of $132.5 million and stated that it has limited working capital and access to financing if cash needs increase unexpectedly.
- Goodwill of $1.8 million was tested for impairment in the fourth quarter and was not impaired. No long-lived-asset impairment was identified.
- Management and BDO USA, LLP concluded that disclosure controls and internal control over financial reporting were effective as of December 28, 2012. BDO issued unqualified audit opinions.
Investor Verification Priorities
- Verify the filing period: the source is fiscal 2012, not fiscal 2011 Q4.
- Assess whether ICL growth can offset declining IOL sales and whether the Korean distributor’s inventory adjustment has reversed.
- Monitor completion costs, regulatory approvals, supply continuity and margin benefits from the Monrovia manufacturing consolidation.
- Confirm renewal and terms of the $5.9 million Mizuho credit facility after its March 28, 2013 expiration.
- Track FDA action on the Toric ICL and the ICL with CentraFLOW technology.
- Evaluate the financial effect of acrylic-lens supplier constraints, product backlogs and any alternative-source qualification.
- Review the sustainability of positive operating cash flow given the 2012 net loss, increased inventory and ongoing capital and pension obligations.
- Consider patent-expiration exposure, regulatory compliance history, product-liability contingencies and the company’s ability to utilize its U.S. tax-loss carryforwards.